公开(公告)号：US20230365558A1

公开(公告)日：2023-11-16

申请号：US18245551

申请日：2021-09-18

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Zuhao GUO ,  Yanxin YU ,  Boyu HU ,  Jingjing WANG ,  Zhaoguo CHEN ,  Cheng XIE ,  Jian XIONG ,  Yongbo FANG ,  Yingtao LIU ,  Jian LI ,  Shuhui CHEN

IPC: C07D471/04 ,  C07D413/12 ,  C07D498/04 ,  C07D498/10 ,  C07D401/12 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D413/12 ,  C07D498/04 ,  C07D498/10 ,  C07D401/12 ,  A61P35/00 ,  C07B2200/13

Abstract: A series of tetrahydroisoquinoline derivatives and the crystal forms thereof. Specifically disclosed are a compound as represented by formula (VII), a crystal form thereof, and a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230055321A1

公开(公告)日：2023-02-23

申请号：US17778533

申请日：2020-11-20

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Shanghua XIA ,  Zhaoguo CHEN ,  Zuhao GUO ,  Yanxin YU ,  Kai ZHOU ,  Boyu HU ,  Li ZHANG ,  Fen JIANG ,  Jingjing WANG ,  Guoping HU ,  Jian LI ,  Shuhui CHEN

IPC: A61K31/519 ,  C07D519/00 ,  A61K45/06 ,  A61K31/55

Abstract: Provided are a class of DNA-PK inhibitor, and specifically, a compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of DNA-PK inhibitor-related drugs.

公开(公告)号：US20210078958A1

公开(公告)日：2021-03-18

申请号：US16955510

申请日：2018-12-19

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X. CHEN ,  XiaWei WEI ,  Li ZHANG ,  Yanxin YU ,  Kai ZHOU ,  Boyu HU ,  Zhaoguo CHEN ,  Huiyu ZHANG ,  Shuhui CHEN

IPC: C07D239/94 ,  C07D409/12 ,  C07D413/12 ,  C07D403/12 ,  C07D405/12 ,  C07D401/12 ,  C07D413/14 ,  C07D498/04 ,  C07D405/14 ,  C07D409/14

Abstract: The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.

公开(公告)号：US20220306622A1

公开(公告)日：2022-09-29

申请号：US17594980

申请日：2020-05-06

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Zhaoguo CHEN ,  Li ZHANG ,  Yanxin YU ,  Kai ZHOU ,  Fen JIANG ,  Shanghua XIA ,  Xiaofei WANG

IPC: C07D471/04

Abstract: Disclosed are a salt and a crystal form of an mTORC1/2 dual kinase inhibitor and a preparation method therefor. Also disclosed is use of the salt and crystal form in the preparation of a medicament related to the mTORC1/2 dual kinase inhibitor.

公开(公告)号：US20210323979A1

公开(公告)日：2021-10-21

申请号：US17053076

申请日：2019-05-08

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Fen JIANG ,  Xinde CHEN ,  Li ZHANG ,  Zhaoguo CHEN ,  Yanxin YU ,  Kai ZHOU ,  Boyu HU ,  Cheng XIE ,  Shuhui CHEN

IPC: C07D519/00 ,  A61P35/00

Abstract: The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20170037050A1

公开(公告)日：2017-02-09

申请号：US15306965

申请日：2015-04-21

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Lingyun WU ,  Yuanshan YAO ,  Zhaoguo CHEN ,  Shuhui CHEN

IPC: C07D487/04 ,  C07D401/12 ,  C07D471/04

CPC classification number: C07D487/04 ,  A61K31/4725 ,  A61K31/55 ,  C07D401/12 ,  C07D471/04

Abstract: The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明公开了一类作为RHO激酶抑制剂的异喹啉磺酰基衍生物及其药物组合物，并且涉及其药学上可接受的用途。 具体而言，本发明涉及由式（I）表示的化合物或其药学上可接受的盐。

公开(公告)号：US20230026616A1

公开(公告)日：2023-01-26

申请号：US17779322

申请日：2020-11-25

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Shanghua XIA ,  Zhaoguo CHEN ,  Zuhao GUO ,  Yanxin YU ,  Kai ZHOU ,  Boyu HU ,  Li ZHANG ,  Fen JIANG ,  Jingjing WANG ,  Guoping HU ,  Jian LI ,  Shuhui CHEN

IPC: C07D519/00 ,  A61P35/00 ,  A61K45/06

Abstract: A class of DNA-PK inhibitors, in particular a compound represented by formula (IV) or a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug relating to a DNA-PK inhibitor.

公开(公告)号：US20200345700A1

公开(公告)日：2020-11-05

申请号：US16479602

申请日：2018-01-24

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Lingyun WU ,  Li ZHANG ,  Lele ZHAO ,  Jianjun SUN ,  Zhaoguo CHEN ,  Jian Ll ,  Shuhui CHEN

IPC: A61K31/4245 ,  A61K33/243 ,  A61P35/00 ,  A61K31/277 ,  C07C255/46 ,  C07D257/04 ,  A61K31/41 ,  A61K31/135 ,  C07C211/40 ,  C07D207/335 ,  A61K31/40 ,  C07D207/09 ,  C07D233/64 ,  A61K31/417 ,  A61K31/4196 ,  C07D249/08 ,  C07D213/38 ,  A61K31/44 ,  A61K31/426 ,  C07D277/28 ,  C07D487/04 ,  A61K31/4188 ,  C07D271/06 ,  A61K31/165 ,  C07C233/58 ,  C07D413/04 ,  A61K31/4439 ,  A61K31/437 ,  C07D471/04 ,  C07D263/56 ,  A61K31/423 ,  A61K31/4375 ,  C07D217/26 ,  A61K31/472 ,  A61K31/451 ,  C07D211/18 ,  C07D211/34 ,  C07D209/44 ,  A61K31/4035 ,  A61K31/55 ,  C07D223/16 ,  C07D261/20 ,  A61K31/519 ,  C07D413/10 ,  C07D417/04 ,  A61K31/428 ,  A61K31/4192 ,  C07D249/06 ,  A61K31/4545 ,  C07D413/14 ,  A61K31/415 ,  C07D231/12 ,  C07D413/06 ,  A61K31/422

Abstract: A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease.

公开(公告)号：US20200339568A1

公开(公告)日：2020-10-29

申请号：US16760740

申请日：2018-11-02

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X CHEN ,  Zhaoguo CHEN ,  Li ZHANG ,  Yanxin YU ,  Kai ZHOU ,  Boyu HU ,  Xiaofei WANG ,  Guoping HU ,  Jian LI ,  Shuhui CHEN

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00

Abstract: Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.